Cargando…
Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial)
BACKGROUND: Patients admitted to intensive care units (ICU) are often treated with intravenous (IV) vasopressors. Persistent hypotension and dependence on IV vasopressors in otherwise resuscitated patients lead to delay in discharge from ICU. Midodrine is an oral alpha-1 adrenergic agonist approved...
Autores principales: | Anstey, Matthew H., Wibrow, Bradley, Thevathasan, Tharusan, Roberts, Brigit, Chhangani, Khushi, Ng, Pauline Yeung, Levine, Alexander, DiBiasio, Alan, Sarge, Todd, Eikermann, Matthias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361788/ https://www.ncbi.nlm.nih.gov/pubmed/28327122 http://dx.doi.org/10.1186/s12871-017-0339-x |
Ejemplares similares
-
Midodrine — why don't you just work better?
por: Anstey, Matthew, et al.
Publicado: (2023) -
Midodrine for orthostatic hypotension
Publicado: (2020) -
Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension
Publicado: (2020) -
Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension
por: Byun, Jung‐Ick, et al.
Publicado: (2019) -
Midodrine to optimize heart failure therapy in patients with
concurrent hypotension
por: Shiu, Paul, et al.
Publicado: (2022)